Morocco overhauls pharmaceutical law to strengthen health sovereignty

Friday 15 May 2026 - 09:04

By: Dakir Madiha

Morocco overhauls pharmaceutical law to strengthen health sovereignty

Morocco has launched a major reform of its pharmaceutical regulatory framework through a new legislative proposal aimed at modernizing the country’s drug and pharmacy code. The draft law was presented on 14 May 2026 before the Social Sectors Committee in the national parliament. It seeks to strengthen national health sovereignty and align domestic regulation with international standards set by global health authorities.

The reform builds on Morocco’s long-term strategy to reinforce pharmaceutical independence and improve drug safety oversight. It follows international recognition of the national medicines regulatory authority at a mature operational level under global assessment standards. The government frames the initiative as part of a broader policy to secure supply chains, improve drug quality control and expand local pharmaceutical production capacity.

The draft legislation introduces four main regulatory pillars. The first establishes a national pharmacovigilance system requiring pharmaceutical institutions to appoint dedicated monitoring officers and obliging healthcare professionals to report adverse drug reactions. The second strengthens post-market surveillance mechanisms, including structured procedures for withdrawing non-compliant medicines and tougher measures against counterfeit or substandard pharmaceutical products.

The third pillar restructures the marketing authorization system by introducing three new licensing categories. These include an export-focused authorization designed to support the growth of the national pharmaceutical industry, a conditional authorization enabling earlier access to selected treatments, and an emergency authorization designed for rapid response during public health crises. The fourth pillar revises financial penalties to better reflect the severity of violations related to medicine safety and regulatory non-compliance.

Authorities say the reform is designed to position the country as a regional hub for pharmaceutical manufacturing and export. The new framework aims to strengthen institutional oversight while aligning national regulations with international health norms. It also reinforces the central role of the national medicines agency in monitoring compliance, approving products and ensuring pharmaceutical safety across the market.